Macroglobulinemia de Waldenström

Solicite una Consulta

Survival rates

Waldenstrom macroglobulinemia survival rates are given by risk group. Other cancers might give survival rates by stage, but stages don't apply to Waldenstrom macroglobulinemia. Instead, healthcare professionals use risk groups to describe the seriousness of the cancer.

To decide on the risk group, the healthcare team uses the person's age and two blood tests, albumin and lactate dehydrogenase (LDH). People in the lower risk groups tend to live longer, while those in higher risk groups have a higher chance of dying of Waldenstrom macroglobulinemia.

Survival rates show the percentage of people with this cancer who are still alive a certain number of years after diagnosis. For example, a five-year survival rate means the percentage of people living five years after diagnosis.

The estimated five-year survival rates for each risk group:

  • Low risk: about 93%.
  • Low-intermediate risk: about 82%.
  • Intermediate risk: about 69%.
  • High risk: about 55%.

Keep in mind that survival statistics take five years to collect. The most recent survival rates include people who had treatment for Waldenstrom macroglobulinemia more than five years ago. These people may not have had access to the latest treatments.

Solicite una consulta
Diagnóstico y tratamientoMédicos y departamentos
Dec. 20, 2025

Living with macroglobulinemia de Waldenström?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

Lori, Volunteer Mentor
My Bone Marrow Transplant (BMT/SCT) story: Will you share yours?

801 Replies Mon, Dec 29, 2025

papa6275
Has anyone had experience with Jakafi?

94 Replies Mon, Dec 29, 2025

See more discussions
  1. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1475. Accessed Nov. 3, 2025.
  2. Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenstrom macroglobulinemia. https://www.uptodate.com/contents/search. Accessed Nov. 3, 2025.
  3. Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma. https://www.uptodate.com/contents/search. Accessed Nov. 3, 2025.
  4. Treatment and prognosis of Waldenstrom macroglobulinemia. https://www.uptodate.com/contents/search. Accessed Nov. 3, 2025.
  5. Elsevier Point of Care. Clinical Overview: Waldenstrom macroglobulinemia. https://www.clinicalkey.com. Accessed Nov. 3, 2025.
  6. Ferri FF. Waldenstrom macroglobulinemia. In: Ferri's Clinical Advisor 2026. Elsevier; 2026. https://www.clinicalkey.com. Accessed Nov. 3, 2025.
  7. Nimmagadda R. EPSi. Mayo Clinic. May 5, 2022.
  8. Elsevier Point of Care. Clinical Overview: Hyperviscosity syndrome. https://www.clinicalkey.com. Accessed Nov. 3, 2025.
  9. Prognosis in Waldenstrom's macroglobulinemia. International Waldenstrom's Macroglobulinemia Foundation. https://iwmf.com/prognosis. Accessed Nov. 13, 2025.

Macroglobulinemia de Waldenström